TY - JOUR
T1 - Avoiding Toxicity With Lung Radiation Therapy
T2 - An IASLC Perspective
AU - International Association for the Study of Lung Cancer Advanced Radiation Technology Committee
AU - Bucknell, Nicholas W
AU - Belderbos, José
AU - Palma, David A
AU - Iyengar, Puneeth
AU - Samson, Pamela
AU - Chua, Kevin
AU - Gomez, Daniel
AU - McDonald, Fiona
AU - Louie, Alexander V
AU - Faivre-Finn, Corinne
AU - Hanna, Gerard G
AU - Siva, Shankar
N1 - Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.
PY - 2022/5/29
Y1 - 2022/5/29
N2 - Toxicity concerns from thoracic radiation therapy in the treatment of lung cancers have changed substantially over the past few decades. Survival in the treatment of lung cancer has markedly improved and the introduction of advanced radiation and imaging techniques to treatment planning and delivery has made reducing toxicity possible. Phase 3 dose-escalation trials have revealed that excess dose to critical organs within the thorax can negatively impact overall survival. We summarize the existing literature on the known toxicities of thoracic radiation therapy, summarize the technological advances that have made toxicity reduction possible, and provide an overview of emerging technologies and biomarkers that are being evaluated to assess future toxicity reductions.
AB - Toxicity concerns from thoracic radiation therapy in the treatment of lung cancers have changed substantially over the past few decades. Survival in the treatment of lung cancer has markedly improved and the introduction of advanced radiation and imaging techniques to treatment planning and delivery has made reducing toxicity possible. Phase 3 dose-escalation trials have revealed that excess dose to critical organs within the thorax can negatively impact overall survival. We summarize the existing literature on the known toxicities of thoracic radiation therapy, summarize the technological advances that have made toxicity reduction possible, and provide an overview of emerging technologies and biomarkers that are being evaluated to assess future toxicity reductions.
U2 - 10.1016/j.jtho.2022.05.003
DO - 10.1016/j.jtho.2022.05.003
M3 - Review article
C2 - 35649502
SN - 1556-0864
JO - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ER -
